Journal Article

Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis

Carolyn M. Shoen, Michelle S. DeStefano, Mary R. Sklaney, Bobbi J. Monica, Andrew M. Slee and Michael H. Cynamon

in Journal of Antimicrobial Chemotherapy

Published on behalf of British Society for Antimicrobial Chemotherapy

Volume 53, issue 4, pages 641-645
Published in print April 2004 | ISSN: 0305-7453
Published online April 2004 | e-ISSN: 1460-2091 | DOI: http://dx.doi.org/10.1093/jac/dkh124
Short-course treatment regimen to identify potential antituberculous agents in a murine model of tuberculosis

Show Summary Details

Preview

Objective: Designing a more rapid method to test antimycobacterial agents in a murine model would significantly improve the drug development process. We describe a short-course in vivo treatment model that could be used to screen potential antituberculous drugs.

Methods: In this model, C57BL/6 mice were infected intranasally with ∼106 viable Mycobacterium tuberculosis organisms. Treatment began 1 day post-infection and was administered for 2 days. Mice were euthanized 3 days post-infection and their right lungs were removed and cell counts determined. Several antimycobacterial agents with superior in vivo activity in a 4 week treatment model were tested to evaluate the short-course treatment model.

Results: Two days of isoniazid (25 mg/kg), rifampicin (20 mg/kg), PNU-100480 (100 mg/kg), gatifloxacin (100 mg/kg), levofloxacin (100 mg/kg) and sparfloxacin (100 mg/kg) were all able to significantly reduce the mycobacterial load in the lungs compared with the untreated control mice.

Conclusions: Use of this model to screen potential chemotherapeutic agents will save time and resources.

Keywords: Keywords: animal models, infectious diseases, Mycobacterium tuberculosis, therapy

Journal Article.  4060 words. 

Subjects: Medical Oncology ; Critical Care

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.